Innovation
A globally first-in-class immunomodulatory drug, classified as a new Category 1 drug.
Indications
Autoimmune diseases, metabolic syndrome, graft-versus-host disease (GvHD), viral pneumonia (including COVID-19), etc.
Research and Development Timeline
2009 Professor Liu Yang's team first discovered the regulatory role of the CD24-Siglec signaling pathway in inflammation responses triggered by tissue damage.
2021 Based on the inflammatory response regulation mechanism of the CD24-Siglec pathway, OncoC4 (AcroImmune) designed a novel Siglec agonist, A1-071.
2022 The product entered the clinical trial phase.